<br>        Inclusion Criteria:<br><br>          -  Subjects who, in the opinion of the investigator, can and will comply with the<br>             requirements of the protocol.<br><br>          -  Written informed consent obtained from the subject prior to performing any study<br>             specific procedure.<br><br>          -  A male or female between, and including, 40 and 80 years of age at the time of the<br>             first vaccination.<br><br>          -  Confirmed diagnosis of COPD with forced expiratory volume in 1 second (FEV1) over<br>             forced vital capacity (FVC) ratio (FEV1/FVC) < 0.7, AND FEV1 < 80% predicted (GOLD 2,<br>             3 and 4).<br><br>          -  Current or former smoker with a cigarette smoking history of = 10 pack-years.<br><br>          -  Stable COPD patient* with documented history** of at least 1 moderate or severe AECOPD<br>             within the 12 months before Screening.<br><br>               -  Patient for whom the last episode of AECOPD is resolved for at least 30 days at<br>                  the time of first vaccination.<br><br>                    -  A documented history of a COPD exacerbation is a medical record of worsening<br>                       COPD symptoms that required systemic/oral corticosteroids and/or antibiotics<br>                       (for a moderate exacerbation) or hospitalization (for a severe<br>                       exacerbation). Prior use of antibiotics alone does not qualify as an<br>                       exacerbation history unless the use was associated with treatment of<br>                       worsening symptoms of COPD, such as increased dyspnea, sputum volume, or<br>                       sputum purulence. Subject verbal reports are not acceptable.<br><br>          -  Capable of complying with the daily electronic Diary Card completion throughout the<br>             study period, according to investigator's judgement at Visit 1.<br><br>          -  Female subjects of non-childbearing potential may be enrolled in the study.<br>             Non-childbearing potential is defined as pre-menarche, current bilateral tubal<br>             ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.<br><br>          -  Female subjects of childbearing potential may be enrolled in the study, if the<br>             subject:<br><br>        has practiced adequate contraception for 30 days prior to vaccination, and has a negative<br>        pregnancy test on the day of vaccination, and has agreed to continue adequate contraception<br>        during the entire treatment period and for 2 months after completion of the vaccination<br>        series.<br><br>        Exclusion Criteria:<br><br>          -  Use of any investigational or non-registered product other than the study vaccine<br>             during the period starting 30 days before the first dose of study vaccine (Day -29 to<br>             Day 1), or planned use during the study period.<br><br>          -  Any medical condition that in the judgment of the investigator would make<br>             intramuscular injection unsafe.<br><br>          -  Administration of immunoglobulins or any blood products within the 3 months preceding<br>             the first dose of study vaccine or planned administration during the study period.<br><br>          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on<br>             medical history and physical examination.<br><br>          -  Planned administration/ administration of a vaccine not foreseen by the study protocol<br>             in the period starting 30 days before the first dose and ending 30 days after the last<br>             dose of vaccine, with the exception of any influenza or pneumococcal vaccine which may<br>             be administered =15 days preceding or following any study vaccine dose.<br><br>          -  Concurrently participating in another clinical study, at any time during the study<br>             period, in which the subject has been or will be exposed to an investigational or a<br>             non-investigational vaccine/product.<br><br>          -  Chronic administration of immunosuppressants or other immune-modifying drugs during<br>             the period starting six months prior to the first vaccine dose (e.g. methotrexate).<br><br>          -  Administration of systemic corticosteroids within the 30 days before first<br>             vaccination.<br><br>        Subjects who received systemic corticosteroids within this period may be enrolled at a<br>        later date if enrolment is still open.<br><br>        Inhaled and topical steroids are allowed.<br><br>        • Administration of systemic antibiotics within the 30 days before first vaccination.<br><br>        Subjects who received systemic antibiotics within this period may be enrolled at a later<br>        date if enrolment is still open.<br><br>          -  Chronic use of antibiotics for prevention of AECOPD (e.g. azithromycin).<br><br>          -  Acute disease and/or fever at the time of first vaccination. Fever is defined as<br>             temperature =37.5°C. The preferred location for measuring temperature in this study<br>             will be the oral cavity or the axilla.<br><br>        Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection)<br>        without fever may be enrolled at the discretion of the investigator.<br><br>          -  Oxygen therapy: Use of long-term oxygen therapy (LTOT) described as resting oxygen<br>             therapy >3L/min (Oxygen use =3L/min flow is not exclusionary).<br><br>          -  Planned lung transplantation.<br><br>          -  Lung resection: Subjects with planned lung volume reduction surgery during the study<br>             or within the 12 months prior to first vaccination.<br><br>          -  Diagnosis of a-1 antitrypsin deficiency as the underlying cause of COPD.<br><br>          -  Diagnosed with a respiratory disorder other than COPD at time of enrolment (such as<br>             sarcoidosis, active tuberculosis, clinically significant bronchiectasis, clinically<br>             significant lung fibrosis, clinically significant pulmonary embolism, clinically<br>             significant pneumothorax, current diagnosis of asthma in the opinion of the<br>             investigator), or chest X-ray/ CT scan revealing evidence of clinically significant<br>             abnormalities not believed to be due to the presence of COPD. Subjects with allergic<br>             rhinitis do not need to be excluded and may be enrolled at the discretion of the<br>             investigator.<br><br>          -  History of immune-mediated disease other than COPD. If the subject has any condition<br>             on the non-exhaustive list of potential immune-mediated diseases defined in the<br>             protocol, they must be excluded unless the aetiology is clearly documented to be<br>             non-immune mediated.<br><br>          -  Previous vaccination with any vaccine containing NTHi and/ or Mcat antigens.<br><br>          -  History of any reaction or hypersensitivity likely to be exacerbated by any component<br>             of the vaccines and/ or the bronchodilator used for spirometry assessment during the<br>             study.<br><br>          -  Contraindication for spirometry testing.<br><br>          -  Unstable or life threatening cardiac disease: subjects with any of the following at<br>             Screening (Visit 1) would be excluded:<br><br>        Myocardial infarction or unstable angina in the last 6 months. Unstable or life threatening<br>        cardiac arrhythmia requiring intervention in the last 3 months NYHA Class IV Heart failure<br><br>          -  Malignancies within the previous 5 years or lymphoproli